vs

Side-by-side financial comparison of Arcturus Therapeutics Holdings Inc. (ARCT) and CPS TECHNOLOGIES CORP (CPSH). Click either name above to swap in a different company.

CPS TECHNOLOGIES CORP is the larger business by last-quarter revenue ($8.2M vs $7.2M, roughly 1.1× Arcturus Therapeutics Holdings Inc.). On growth, CPS TECHNOLOGIES CORP posted the faster year-over-year revenue change (38.3% vs -68.4%). CPS TECHNOLOGIES CORP produced more free cash flow last quarter ($-487.0K vs $-74.5M). Over the past eight quarters, CPS TECHNOLOGIES CORP's revenue compounded faster (17.8% CAGR vs -56.5%).

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.

Lesaka Technologies is a South-African financial technology company that is listed on the NASDAQ and Johannesburg Stock Exchange. Lesaka’s primary focus is on financial inclusion, offering financial services to previously underserved communities and merchants.

ARCT vs CPSH — Head-to-Head

Bigger by revenue
CPSH
CPSH
1.1× larger
CPSH
$8.2M
$7.2M
ARCT
Growing faster (revenue YoY)
CPSH
CPSH
+106.7% gap
CPSH
38.3%
-68.4%
ARCT
More free cash flow
CPSH
CPSH
$74.0M more FCF
CPSH
$-487.0K
$-74.5M
ARCT
Faster 2-yr revenue CAGR
CPSH
CPSH
Annualised
CPSH
17.8%
-56.5%
ARCT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ARCT
ARCT
CPSH
CPSH
Revenue
$7.2M
$8.2M
Net Profit
$12.6K
Gross Margin
14.9%
Operating Margin
-1.2%
Net Margin
0.2%
Revenue YoY
-68.4%
38.3%
Net Profit YoY
3.1%
101.3%
EPS (diluted)
$0.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARCT
ARCT
CPSH
CPSH
Q4 25
$7.2M
$8.2M
Q3 25
$17.2M
$8.8M
Q2 25
$28.3M
$8.1M
Q1 25
$29.4M
$7.5M
Q4 24
$22.8M
$5.9M
Q3 24
$41.7M
$4.2M
Q2 24
$49.9M
$5.0M
Q1 24
$38.0M
$5.9M
Net Profit
ARCT
ARCT
CPSH
CPSH
Q4 25
$12.6K
Q3 25
$-13.4M
$208.0K
Q2 25
$-9.2M
$103.8K
Q1 25
$-14.1M
$96.0K
Q4 24
$-30.0M
$-995.2K
Q3 24
$-6.9M
$-1.0M
Q2 24
$-17.2M
$-954.3K
Q1 24
$-26.8M
$-143.2K
Gross Margin
ARCT
ARCT
CPSH
CPSH
Q4 25
14.9%
Q3 25
17.1%
Q2 25
16.5%
Q1 25
16.4%
Q4 24
-4.6%
Q3 24
-12.3%
Q2 24
-4.6%
Q1 24
15.3%
Operating Margin
ARCT
ARCT
CPSH
CPSH
Q4 25
-1.2%
Q3 25
-96.3%
3.1%
Q2 25
-41.0%
1.7%
Q1 25
-57.3%
1.7%
Q4 24
-146.7%
-22.2%
Q3 24
-25.8%
-35.0%
Q2 24
-42.4%
-26.1%
Q1 24
-80.0%
-4.4%
Net Margin
ARCT
ARCT
CPSH
CPSH
Q4 25
0.2%
Q3 25
-78.4%
2.4%
Q2 25
-32.4%
1.3%
Q1 25
-47.9%
1.3%
Q4 24
-131.8%
-16.8%
Q3 24
-16.6%
-24.6%
Q2 24
-34.5%
-19.0%
Q1 24
-70.5%
-2.4%
EPS (diluted)
ARCT
ARCT
CPSH
CPSH
Q4 25
$0.00
Q3 25
$-0.49
$0.01
Q2 25
$-0.34
$0.01
Q1 25
$-0.52
$0.01
Q4 24
$-1.10
$-0.07
Q3 24
$-0.26
$-0.07
Q2 24
$-0.64
$-0.07
Q1 24
$-1.00
$-0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARCT
ARCT
CPSH
CPSH
Cash + ST InvestmentsLiquidity on hand
$230.9M
$13.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$214.0M
$24.6M
Total Assets
$271.1M
$29.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARCT
ARCT
CPSH
CPSH
Q4 25
$230.9M
$13.2M
Q3 25
$180.4M
$4.3M
Q2 25
$196.5M
$3.4M
Q1 25
$216.9M
$3.0M
Q4 24
$237.0M
$4.3M
Q3 24
$237.2M
$5.7M
Q2 24
$260.3M
$7.1M
Q1 24
$288.4M
$8.7M
Total Debt
ARCT
ARCT
CPSH
CPSH
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$8.1K
Q3 24
$20.1K
Q2 24
$31.9K
Q1 24
$43.5K
Stockholders' Equity
ARCT
ARCT
CPSH
CPSH
Q4 25
$214.0M
$24.6M
Q3 25
$224.6M
$15.1M
Q2 25
$231.1M
$14.9M
Q1 25
$233.8M
$14.7M
Q4 24
$241.0M
$14.5M
Q3 24
$261.9M
$15.4M
Q2 24
$258.6M
$16.4M
Q1 24
$264.0M
$17.3M
Total Assets
ARCT
ARCT
CPSH
CPSH
Q4 25
$271.1M
$29.5M
Q3 25
$282.3M
$20.4M
Q2 25
$309.3M
$19.4M
Q1 25
$331.8M
$19.2M
Q4 24
$344.1M
$18.9M
Q3 24
$370.7M
$19.2M
Q2 24
$388.6M
$20.1M
Q1 24
$418.8M
$21.2M
Debt / Equity
ARCT
ARCT
CPSH
CPSH
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARCT
ARCT
CPSH
CPSH
Operating Cash FlowLast quarter
$-74.3M
$243.6K
Free Cash FlowOCF − Capex
$-74.5M
$-487.0K
FCF MarginFCF / Revenue
-1035.2%
-5.9%
Capex IntensityCapex / Revenue
3.2%
8.9%
Cash ConversionOCF / Net Profit
19.34×
TTM Free Cash FlowTrailing 4 quarters
$-479.6K

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARCT
ARCT
CPSH
CPSH
Q4 25
$-74.3M
$243.6K
Q3 25
$-17.2M
$1.1M
Q2 25
$-5.8M
$649.3K
Q1 25
$-35.1M
$-1.3M
Q4 24
$-284.0K
$-3.5M
Q3 24
$-23.8M
$-1.2M
Q2 24
$-30.1M
$-1.0M
Q1 24
$-5.6M
$128.9K
Free Cash Flow
ARCT
ARCT
CPSH
CPSH
Q4 25
$-74.5M
$-487.0K
Q3 25
$-17.3M
$876.8K
Q2 25
$476.4K
Q1 25
$-35.3M
$-1.3M
Q4 24
$-4.5M
Q3 24
$-23.8M
$-1.3M
Q2 24
$-30.5M
$-1.6M
Q1 24
$-5.8M
$-134.5K
FCF Margin
ARCT
ARCT
CPSH
CPSH
Q4 25
-1035.2%
-5.9%
Q3 25
-101.1%
10.0%
Q2 25
5.9%
Q1 25
-120.1%
-17.9%
Q4 24
-75.3%
Q3 24
-57.2%
-29.8%
Q2 24
-61.1%
-31.8%
Q1 24
-15.3%
-2.3%
Capex Intensity
ARCT
ARCT
CPSH
CPSH
Q4 25
3.2%
8.9%
Q3 25
1.1%
2.0%
Q2 25
0.0%
2.1%
Q1 25
0.5%
1.2%
Q4 24
0.0%
16.8%
Q3 24
0.2%
1.9%
Q2 24
0.7%
11.0%
Q1 24
0.6%
4.5%
Cash Conversion
ARCT
ARCT
CPSH
CPSH
Q4 25
19.34×
Q3 25
5.05×
Q2 25
6.25×
Q1 25
-13.05×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons